Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H1, 2017

Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H1, 2017


  • Products Id :- GDHC4118CTIDB
  • |
  • Pages: 203
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H1, 2017

Summary

GlobalData's clinical trial report, "Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H1, 2017" provides an overview of Amyotrophic Lateral Sclerosis clinical trials scenario. This report provides top line data relating to the clinical trials on Amyotrophic Lateral Sclerosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global clinical trials landscape

Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

The Report provides enrollment trends for the past five years

Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 5

Clinical Trials by Region 6

Clinical Trials and Average Enrollment by Country 7

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10

Top Five Countries Contributing to Clinical Trials in Europe 11

Top Countries Contributing to Clinical Trials in North America 12

Top Countries Contributing to Clinical Trials in Middle East and Africa 13

Top Countries Contributing to Clinical Trials in Central and South America 14

Clinical Trials by G7 Countries: Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials 15

Clinical Trials by Phase in G7 Countries 17

Clinical Trials in G7 Countries by Trial Status 18

Clinical Trials by E7 Countries: Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials 19

Clinical Trials by Phase in E7 Countries 21

Clinical Trials in E7 Countries by Trial Status 22

Clinical Trials by Phase 23

In Progress Trials by Phase 24

Clinical Trials by Trial Status 25

Clinical Trials by End Point Status 27

Subjects Recruited Over a Period of Time 28

Clinical Trials by Sponsor Type 29

Prominent Sponsors 30

Top Companies Participating in Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials 32

Prominent Drugs 34

Latest Clinical Trials News on Amyotrophic Lateral Sclerosis 35

Mar 23, 2017: Confidential Data from Genervon ALS Phase 2A Clinical Trial Were Released and Published 35

Mar 07, 2017: AB Science Announces That Frontiers In Aging Neuroscience Publishes A Comprehensive Review On The Future Potential Of Masitinib In Amyotrophic Lateral Sclerosis 35

Mar 01, 2017: BrainStorm Announces MOU with Tel Aviv Sourasky Medical Center to Make NurOwn Available to Patients as a Hospital Exemption Product 35

Feb 27, 2017: BrainStorm Names Dr. June S. Almenoff and Arturo O. Araya to its Board of Directors as Company Prepares for Clinical and Commercial Success 36

Feb 16, 2017: City of Hope to Manufacture NurOwn for Brainstorm's Phase 3 ALS Clinical Trial 36

Feb 08, 2017: Neuraltus Pharmaceuticals Provides Enrollment Update on Confirmatory Phase 2 Study of NP001 in ALS 37

Jan 30, 2017: BrainStorm Announces Validation of NurOwn Cryopreservation Process 37

Jan 24, 2017: Flex Pharma Focuses on Phase 2 Clinical Programs in Severe Neurological Diseases 37

Jan 03, 2017: New Preclinical Data Demonstrate That Masitinib Has An Unexpected Protective Effect On Muscles And Nerves In Amyotrophic Lateral Sclerosis 37

Clinical Trial Profile Snapshots 39

Appendix 201

Abbreviations 201

Definitions 201

Research Methodology 202

Secondary Research 202

About GlobalData 203

Contact Us 203

Source 203

List of Figures

Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Region (%), 2017* 6

Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 7

Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9

Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 10

Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 11

Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 12

Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 13

Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2017* 14

Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials, G7 Countries (%), 2017* 15

Amyotrophic Lateral Sclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17

Amyotrophic Lateral Sclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18

Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials, E7 Countries (%), 2017* 19

Amyotrophic Lateral Sclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 21

Amyotrophic Lateral Sclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 22

Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Phase (%), 2017* 23

Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 24

Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2017* 25

Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2017* 27

Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 28

Amyotrophic Lateral Sclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 29

Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 30

Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 32

Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 34

GlobalData Methodology 202

List of Tables

Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Region, 2017* 6

Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8

Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9

Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 10

Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 11

Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, North America, Top Countries, 2017* 12

Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 13

Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 14

Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials, G7 Countries (%), 2017* 16

Amyotrophic Lateral Sclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17

Amyotrophic Lateral Sclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18

Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials, E7 Countries (%), 2017* 20

Amyotrophic Lateral Sclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 21

Amyotrophic Lateral Sclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 22

Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Phase, 2017* 23

Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 24

Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2017* 26

Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2017* 27

Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 28

Amyotrophic Lateral Sclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 29

Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 31

Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 33

Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 34

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Cytokinetics Inc, Knopp Biosciences LLC, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd, Newron Pharmaceuticals SpA, Biogen Inc, BrainStorm Cell Therapeutics Inc, Neuralstem Inc, Flex Pharma Inc, Aeolus Pharmaceuticals Inc

Amyotrophic Lateral Sclerosis Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO's, Terminated, Suspended and Withdrawn trials of Amyotrophic Lateral Sclerosis, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania.

select a license

Single User License
USD 2500 INR 161425
Site License
USD 5000 INR 322850
Corporate User License
USD 7500 INR 484275

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com